Inhibition of this pathway can also be a promising strategy, as the mutation and increased activity of PI3K catalytic subunit (PIK3CA) have been associated with resistance of tumor cells to EGFR inhibitors, and such mutation is harbored by 5–15% of head and neck cancer cases [14,15]. This evidence concerns the gene PIK3CA and head and neck cancer.